Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Canada

Research and Innovation Action · Running

PHAGE4DAIR A multicenter, double-blind Phase I/II trial evaluating safety and efficacy of a fixed phage cocktail vs. placebo + DAIR in treating S. aureus prosthetic joint infections.

Coordinator
Qeen Biotechnologies Inc., Canada
Runs
1 June 2026 to 31 May 2031
Status
Running
EU funding
€14.9m
Total cost
—
Partners
25 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101287116

What the project is doing

In the project's own words, from its summary on CORDIS.

PHAGE4DAIR: Phage therapy for Arthroplasty infections using Local and Conservative surgery (DAIR)PHAGE4DAIR is a multicenter, randomized, double-blind, placebo-controlled, adaptive Phase I/II clinical trial evaluating the safety and preliminary efficacy of a GMP-manufactured 5-phage cocktail targeting Staphylococcus aureus in prosthetic joint infections (PJI) treated using DAIR (Debridement, Antibiotics, and Implant Retention).

Acute S. aureus PJI represents approximately 23% of prosthetic hip and knee infections, with DAIR performed in over 40% of acute cases . Despite its conservative advantages, DAIR is associated with high failure rates, especially in antibiotic-resistant infections, underscoring the urgent need for novel adjunctive therapeutics. This Horizon Europe trial integrates a seamless Bayesian adaptive design to evaluate dose, route, and treatment efficacy over time.

The investigational phage cocktail is already under IND in the United States for related indications, facilitating transatlantic regulatory alignment. Patients will be enrolled based on confirmed S. aureus infection undergoing DAIR, with phages administered intraoperatively and intravenously alongside standard-of-care antibiotics. Co-primary endpoints include safety and clinical cure 3 months post-antibiotic completion.

PHAGE4DAIR will generate high-quality clinical, PK/PD, immunological, and microbiological data to support regulatory decision-making. The consortium includes leaders in GMP manufacturing, clinical trials, and regulatory science. A robust dissemination, exploitation, and regulatory strategy ensures a clear pathway to EMA Scientific Advice, stakeholder engagement, and future Phase III readiness. The project directly supports Horizon Europe’s goal to accelerate phage-based solutions for antimicrobial resistance and foster biotech innovation for difficult-to-treat infections.

Topics

Who is involved

OrganisationCityCountryRole
Qeen Biotechnologies Inc.GatineauCanadaCoordinator
European Hip SocietyInnsbruckAustriaAssociatedpartner
Medizinische Universitaet WienWienAustriaParticipant
Canadian Arthroplasty SocietyWestmountCanadaAssociatedpartner
Ottawa Hospital Research Institute CorporationOttawa OntarioCanadaParticipant
The Governors of the University of AlbertaEdmontonCanadaParticipant
Unity Health TorontoTorontoCanadaParticipant
University of CalgaryCalgary AlbertaCanadaParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Aristotelio Panepistimio ThessalonikisThessalonikiGreeceParticipant
Centre Hospitalier Universitaire De NiceNiceFranceParticipant
Hospices Civils De LyonLyonFranceParticipant
Universite Lyon 1 Claude BernardVilleurbanne CedexFranceParticipant
Academisch Ziekenhuis GroningenGroningenNetherlandsParticipant
Acibadem Mehmet Ali Aydinlar UniversityIstanbulTürkiyeAssociatedpartner
Bone and Joint Infection SocietyLondonUnited KingdomAssociatedpartner
Centre for Process Innovation Limited LbgRedcar ClevelandUnited KingdomParticipant
Cambridge University Hospitals NHS Foundation TrustCambridgeUnited KingdomParticipant
Micron Research LimitedElyUnited KingdomParticipant
The Royal National Orthopaedic Hospital National Health Service TrustStanmoreUnited KingdomParticipant
The University of ExeterExeterUnited KingdomParticipant
University College LondonLondonUnited KingdomParticipant
University College London Hospitalsnhs Foundation TrustLondonUnited KingdomParticipant
University Hospital Birmingham Nhs Foundation TrustBirminghamUnited KingdomParticipant
Mayo ClinicRochesterUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI